On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine, can now be used "for the treatment of depression in adults who have tried other antidepressant ...

Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy ... differences of -5.1 with the 56-mg dose and -6.8 with ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

It's called Spravato, made by Johnson and Johnson and it works faster than standard oral antidepressants. Spravato was first approved back in 2019, but at that time, patients had to use it with an ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

Spravato generated full-year sales of $689 million in 2023, an 84% increase from $374 million the year before.